Earnings Summary

Deciphera Pharmaceuticals, Inc.’s revenue jumped 17.88% since last year same period to $38.3Mn in the Q2 2023. On a quarterly growth basis, Deciphera Pharmaceuticals, Inc. has generated 14.53% jump in its revenue since last 3-months.

Deciphera Pharmaceuticals, Inc.’s net profit fell -12.77% since last year same period to $-48.56Mn in the Q2 2023. On a quarterly growth basis, Deciphera Pharmaceuticals, Inc. has generated -5.66% fall in its net profits since last 3-months.

Deciphera Pharmaceuticals, Inc.’s net profit margin jumped 4.33% since last year same period to -126.78% in the Q2 2023. On a quarterly growth basis, Deciphera Pharmaceuticals, Inc. has generated 7.74% jump in its net profit margins since last 3-months.

Deciphera Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.58 - a 0% jump from last quarter’s estimates.

Deciphera Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.58.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Deciphera Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.24.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Deciphera Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.46.